Side Effects Guide
WIKI · INCIDENCE DATA FROM STEP-1 · MANAGEMENT FROM COMMUNITY + GUIDELINES
Most GLP-1 side effects are gastrointestinal, dose-dependent, and front-loaded around titration steps. Here is what the trial data actually shows, and what the community has learned about managing it.
⚕ Not medical advice. The GLP Lounge is a community forum. Nothing on this page is a substitute for guidance from a licensed clinician. Always involve your prescriber before starting, stopping, or changing a medication.
Adverse event incidence — semaglutide 2.4 mg vs placebo
STEP-1 (68 weeks, n=1,961) — any-grade events
Nausea44%
placebo17%
Diarrhea30%
placebo16%
Vomiting24%
placebo6%
Constipation24%
placebo11%
Wilding et al., NEJM 2021. Serious GI events were uncommon; discontinuation for GI reasons: 4.5% vs 0.8% placebo.
Management that actually has evidence
| Symptom | Typical onset | First-line management |
|---|
| Nausea | 48–72 h post-injection, worse at titration | Smaller meals, stop at 80% full, avoid high-fat meals, ginger; ondansetron short-term if prescribed |
| Constipation | Weeks 2+ | Fluids + soluble fiber (psyllium), magnesium glycinate at night, movement |
| Reflux / burping | Any time | Earlier dinner, smaller portions; famotidine/PPI per clinician |
| Fatigue | Titration weeks | Check calorie floor, protein, hydration, electrolytes; usually transient |
| Injection-site reaction | Immediate | Rotate sites (abdomen/thigh/arm), room-temp pen, fresh needle every time |
Protecting lean mass
- Resistance training 2–4×/week — an RCT in this population showed it prevents the majority of lean-mass loss.
- Protein 1.2–1.6 g/kg/day; spread across 3–4 feedings.
- Track with DEXA if you can — scale weight alone hides composition. Compare with others in Exercise & Body Composition.
Red-flag symptoms — involve a clinician immediately
- Severe, persistent abdominal pain radiating to the back (± vomiting) — rule out pancreatitis.
- Right-upper-quadrant pain, fever, jaundice — gallbladder disease risk rises with rapid weight loss.
- Inability to keep fluids down >24 h — dehydration and AKI risk.
- Severe hypoglycemia symptoms if combined with insulin or sulfonylureas.
- Vision changes in people with diabetic retinopathy.
Compare experiences and mitigation protocols in
Side Effects & Management — but report red-flag symptoms to a clinician, not a forum.